Trial Profile
A Phase I/II Study of Pembrolizumab and Vorinostat in Patients With Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Vorinostat (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Feb 2024 Planned End Date changed from 21 Jan 2024 to 21 Jan 2025.
- 21 Sep 2023 Planned End Date changed from 1 Jan 2024 to 21 Jan 2024.
- 21 Sep 2023 Planned primary completion date changed from 1 Jan 2024 to 21 Jan 2024.